Genmab (GMAB) investor relations material

Key business and pipeline updates

• Revenue-generating medicines increased to nine, with three late-stage assets expanding reach and six new phase III trials announced this year.

• All three lead programs are expected to generate phase III data in Q4, with multiple commercial launches planned for next year, contingent on positive results.

• Revenue rose 25% and operating profit 18% in the first half, supporting further investment in late-stage programs and commercial preparations.

Petosemtamab program highlights

• Petosemtamab, a next-generation EGFR bispecific, shows higher efficacy and better safety compared to competitors, with two phase III trials in head and neck cancer and two in colorectal cancer underway.

• Phase III top-line data for frontline head and neck cancer expected in Q4, with additional data on safety and patient subsets to follow at medical conferences.

• Enrollment in LiGeR trials was increased to capture sufficient patient diversity, with no impact on enrollment timing.

• Anticipation is high for phase III results, as phase II data showed a 63% response rate, 9-month median PFS, and 79% 12-month OS, potentially setting a new standard of care.

• Over 300 sites and major investigators are involved in the petosemtamab program, ensuring broad familiarity and collaboration.

Colorectal cancer (CRC) trial developments

• Two phase III trials in CRC are underway: a 900-patient frontline study and a second-line study, both comparing petosemtamab combinations to standard regimens.

• Petosemtamab was selected for CRC based on Wnt pathway biology and promising organoid screening data.

• CRC market potential is estimated at three times that of head and neck cancer, with high response rates observed in early data.

• Frontline response rates for petosemtamab plus chemotherapy are in the high 80s, and second-line rates are 60–70%, both exceeding current standards.